New cholesterol drugs show promise in Late-Stage trial

NCT ID NCT06717360

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 3 trial tested two new drugs, AG2304T and AG2304R, in 158 adults with primary hypercholesterolemia (high cholesterol). The study compared these drugs to an active control to see how well they lower LDL cholesterol and to check for side effects. Results could offer a new option for managing high cholesterol.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AG2304T and AG2304R (cholesterol-lowering drugs)

What this could lead to

If successful, this could provide a new treatment option for people with high cholesterol, helping to lower LDL cholesterol levels.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. The drugs may not prove more effective or safer than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AhnGook

    Seoul, South Korea